LIU Update: Visit here for more information.

Faculty & Research Interests


Adolfo Quiñones Lombraña, Ph.D.
Research Assistant Professor, Pharmaceutical Sciences
(718) 780-6042


Ph.D., Biochemistry/Molecular Biology, Complutense University of Madrid, Spain

Short Biography
Dr. Quiñones Lombraña received his BSc in Molecular Biology from the University of Oviedo (Spain) in 2004. After earning his bachelor’s degree, Dr. Quiñones Lombraña has held different positions at the Institute of Biology of Leiden University (Leiden, Netherlands) and the University Institute of Oncology of Asturias (Oviedo, Spain). He continued his scientific career at the Hospital 12 de Octubre (Madrid) while pursued his Ph.D. in Molecular Biology at the Complutense University of Madrid (Spain). His Ph.D. project resulted in the functional characterization of the addiction-related gene ANKK1. This work unraveled a novel scenario to help understanding neuropsychiatric disorders providing, for the first time, an evidence of the association between the expression of ANKK1 and the dopaminergic system. Before joining Arthur G. Zupko's Division of Systems Pharmacology and Pharmacogenomics in the Arnold & Marie Schwartz College of Pharmacy and Health Science at LIU, he was appointed as Research Associate at the Pharmaceutical Sciences Department of the State University of New York at Buffalo. During his tenure, Dr. Quiñones Lombraña has analyzed the role of genetics in the development of cardiac issues in cancer patients exposed to chemotherapeutic drugs. His translational research has integrated clinical data and informative laboratory models to understand why adverse effects arises in certain patients after chemotherapy while others identically treated do not show any symptom. Dr. Quiñones Lombraña has also collaborated with investigators within the prestigious Children’s Oncology Group to perform large-scale pharmacogenetic research in pediatric oncology. Dr. Quiñones Lombraña’s studies have determined the functional relevance of different gene variants in order to better understand the pathogenesis of cardiac dysfunction.

Research Synopsis
Pharmacogenomics: Variability in drug response suggests that genetic predisposition plays a role in the effects of multiple drugs. Characterization of genetic and epigenetic factors that contribute to variable drug response in relevant clinical settings would allow developing new risk prediction tools and therapeutic targets that will help to predict who will benefit from a medication, who will not respond at all, and who will experience negative side effects.

Recent Publications

  • Cejas R., Ferguson D., Quiñones-Lombraña A., Bard, J., Blanco JG. Contribution of DNA methylation to the expression of FCGRT in human liver and myocardium. Scientific Reports. 2019 Jun; 9(1):8674
  • Quiñones-Lombraña A., Blanco JG. Comparative analysis of the DYRK1A-SRSF6-TNNT2 pathway in myocardial tissue from individuals with and without Down syndrome. Experimental and Molecular Pathology. 2019 Jun; 11:104268.
  • Quiñones-Lombraña A., Intini A, Blanco JG. Insights into the transcriptional regulation of the anthracycline reductase AKR7A2 in human cardiomyocytes. Toxicology Letters. 2019 Jun; 307:11-16.
  • Walitzer KS., Stewart S., Blanco JG., Swiatek D., Hughes LP., Quiñones-Lombraña A., Shyhalla K. Medication-enhanced behavior therapy for alcohol use disorder: Naltrexone, alcoholics anonymous facilitation, and OPRM1 genetic variation. Journal of Substance Abuse Treatment 2019 May; 104: 7 - 14 4.
  • Quiñones-Lombraña A., Li N., del Solar V., Atilla‚ÄźGokcumen GE., Blanco JG. CBR1 rs9024 genotype status impacts the bioactivation of loxoprofen in human liver. Biopharmaceutics and Drug Disposition 2018 Jun; 39(6): 315-318.
  • Quiñones-Lombraña A., Blair RH., Blanco JG. Investigation of the Role of DNA Methylation in the Expression of ERBB2 in Human Myocardium. Gene 2017 Sep; 628: 286-294.
  • Quiñones-Lombraña A., Cheng Q., Ferguson DC., Blanco JG. Transcriptional Regulation of the Canine Carbonyl Reductase 1 Gene (cbr1) by the Specificity Protein 1 (Sp1). Gene 2016 Oct; 592(1): 209-214.
  • Ponce G., Quiñones-Lombraña A., Martín-Palanco NG., Rubio-Solsona E., Jiménez-Arriero MA., Palomo T., Hoenicka J. The Addiction-related Gene ANKK1 Is Oppositely Regulated by D1R- and D2-R-like Dopamine Receptors. Neurotoxicity Research 2016 Apr; 29 (3): 345-50.
  • Hoefer CC., Quiñones-Lombraña A., Blair RH., Blanco JG. Role of DNA Methylation on the Expression of Anthracycline Metabolizing Enzyme AKR7A2 in human heart. Cardiovascular Toxicology 2016 Apr; 16 (2): 182-92.
  • Wang X., Sun CL., Quiñones-Lombraña A., Singh P., Landier W., Hageman L., Mather M., Rotter JI., Taylor KD., Chen YD., Armenian SH., Winick N., Ginsberg JP., Neglia JP., Oeffinger KC., Castellino SM., Dreyer ZE., Hudson MM., Robison LL., Blanco JG., Bhatia S J. CELF4 variant and Anthracycline-related Cardiomyopathy – A Children’s Oncology Group Study. Journal of Clinical Oncology 2016 Mar; 34(8): 863-870.
  • Hefti E., Quiñones-Lombraña A., Redzematovic A., Hui J., Blanco JG. Analysis of mtDNA, miR-155 and BACH1 expression in hearts from donors with- and without- Down syndrome. Mitochondrial DNA A DNA Mapp Seq Anal. 2016; 27(2):896-903.
  • Quiñones-Lombraña A., Blanco JG. Chromosome 21-derived hsa-miR-155-5p regulates mitochondrial biogenesis by targeting Mitochondrial Transcription Factor A (TFAM). BBA Molecular Basis of disease. 2015 Jul;1852(7): 1420-7.
  • Quiñones-Lombraña A., Ferguson D., Blair RH., Kalabus JL., Redzematovic A., Blanco JG. Interindividual Variability in the Cardiac Expression of Anthracycline Reductases in Donors with- and without- Down Syndrome. Pharmaceutical Research 2014 Jul; 31(7): 1644-55.
  • Wang X., Liu W., Sun CL., Armenian SH., Hakonarson H., Hageman L., Ding Y., Landier W., Blanco JG., Chen L, Quiñones A., Ferguson D., Winick N., Ginsberg JP., Keller F., Neglia JP., Desai S., Sklar CA., Castellino SM., Cherrick I., Dreyer ZE., Hudson MM., Robison LL., Yasui Y., Relling MV., Bhatia S. Hyaluronidase synthase 3 (HAS3) variant and Anthracycline-related Cardiomyopathy – A Report from the Children’s Oncology Group. Journal of Clinical Oncology 2014 Mar; 32(7): 647-53.
  • del Solar V., Quiñones-Lombraña A., Cabrera S., Padrón JM., Ríos-Luci C., Alvarez-Valdés A., Navarro-Ranninger C., Alemán J. Expanding the Synthesis of New trans-Sulfonamide Platinum Complexes: Cytotoxicity, SAR, Fluorescent Cell Assays and Stability Studies. Journal of Inorganic Biochemistry 2013 Oct; 127: 128-40.
  • Hoenicka J., Quiñones-Lombraña A., España-Serrano L., Alvira-Botero X., Kremer L., Pérez-González R., Rodríguez-Jiménez R., Jiménez-Arriero MA., Ponce G., Palomo T. The ANKK1 Gene Associated with Addictions Is Expressed in Astroglial Cells and Upregulated by Apomorphine. Biological Psychiatry 2010 Jan; 67(1): 3-11.
  • Quiñones-Lombraña A., Lopez-Soto A., Ballina-Garcia FJ., Alperi-López M., Queiro-Silva R., Lopez-Vazquez A., Lopez-Larrea C., Gonzalez S. BAT1 Promoter Polymorphism is associated with rheumatoid arthritis susceptibility. Journal of Rheumatology 2008 May; 35(5): 741-4.
  • López-Arbesu R., Ballina-García FJ., Alperi-López M., López-Soto A., Rodríguez-Rodero S., Martínez-Borra J., López-Vázquez A., Fernández-Morera JL., Riestra-Noriega JL., Queiro-Silva R., Quiñones-Lombraña A., López-Larrea C., González S. MHC class I chain-related gene B (MICB) is associated with rheumatoid arthritis susceptibility. Rheumatology (Oxford) 2007 Mar; 46(3):426-30.
  • López-Soto A., Quiñones-Lombraña A., López-Arbesú R., López-Larrea C., González S. Transcriptional regulation of ULBP1, a human ligand of the NKG2D receptor. Journal of Biological Chemistry 2006 Oct; 281(41): 30419-30.


LIU Pharmacy
Arash T. Dabestani